Abstract

Background: Management guidelines about the thyroid disease in pregnancy are silent about the postpartum course of new onset subclinical hypothyroidism (SCH). Hence, we analyzed the 2 years outcome of SCH diagnosed during pregnancy. Materials and Methods: We conducted this retrospective study using the medical records of patients with new onset SCH during pregnancy between 2010 and 2013 (n = 718). Patients who stopped their levothyroxine after delivery with a 2-year follow-up record were included. We excluded patients with known thyroid disorders and continuous use of drugs that affect the thyroid results. The patients were divided into two groups (Group 1 – euthyroid and Group 2 – hypothyroid) based on the final outcome after 2 years. The data were analyzed using appropriate statistical methods and a P < 0.05 was considered statically significant. Results: A total of 559 (77.8%) women stopped levothyroxine after delivery, and the final follow-up data were available for 467 patients only. At the end of 2 years, 384 (82.2%) remained euthyroid, and the remaining 83 (17.8%) developed hypothyroidism. SCH and overt hypothyroidism were seen in 22 and 61 patients, respectively. Group 2 patients had higher mean age (25.5 vs. 23.6 years), goiter (51 vs. 2%), initial thyroid stimulating hormone (7.9 vs. 5.1 µIU/mL), and thyroid antibody positivity (76 vs. 13%) (P < 0.001). Conclusion: The majority of patients with SCH during pregnancy remain euthyroid after delivery. Advanced age, goiter, positive family history, and thyroid autoimmunity increase the future risk of hypothyroidism in patients with SCH diagnosed during pregnancy.

Keywords: Autoimmunity, pregnancy, subclinical hypothyroidism, thyroid

Introduction

Subclinical hypothyroidism (SCH) and autoimmune thyroid disease (AITD) are associated with adverse pregnancy outcomes. SCH has also been shown to affect the long-term neuropsychological and intellectual development of the newborn. Increasing awareness about the thyroid disease and wide availability of thyroid hormone estimation led to increased number of women with SCH and AITD in pregnancy. Few reports exist from our country about the prevalence and the complications of SCH in pregnancy. The issue has been debated extensively in the last few years leading to the release of management guidelines from many international societies. Most of the guidelines recommend treatment with levothyroxine keeping the thyroid stimulating hormone (TSH) in the gestational age specific range. However, the guidelines are not very clear about the postpartum management of the patients diagnosed with the SCH during pregnancy. Pregnancy leads to an increase in the requirement of the thyroid hormone, and the increasing requirement is not well defined during the postpartum period.

The natural course of the SCH in nonpregnant individuals has been identified clearly. One-third of the patients remain SCH, another third progress to overt hypothyroidism (OH) and the remaining third improve to have normal thyroid function. The diagnosis of the SCH in pregnancy is based on the trimester-specific cutoff values of the TSH. Similar to the nonpregnant individuals, the pregnant women with SCH may improve, remain with SCH or progress to hypothyroidism after delivery. Indian obstetric care is burdened with poor postpartum follow-up and early unplanned next pregnancy. In this scenario, it is important to identify the women, who are

Address for correspondence: K. Neelaveni, Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, India. E-mail: neelaveni1@yahoo.co.in

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Neelaveni K, Kumar KH, Sahay R, Ramesh J. Postpartum follow-up in women diagnosed with subclinical hypothyroidism during pregnancy. Indian J Endocr Metab 2017;21:699-702.
at a higher risk of developing hypothyroidism in subsequent pregnancy. This knowledge helps in planning the management strategy after pregnancy and prevents the adverse impact of the undetected thyroid dysfunction. Hence, we evaluated the course of new onset SCH diagnosed during pregnancy and the risk factors of progression to hypothyroidism.

**MATERIALS AND METHODS**

**Study population**
We conducted this retrospective study using the medical records in a tertiary care, teaching hospital. The records pertaining to the patients between January 2010 and June 2013, who attended the endocrinology clinic for the new onset SCH during pregnancy, were included. A total of 718 patients with a diagnosis of SCH during pregnancy were evaluated, and the study protocol with salient findings is shown in Figure 1. We excluded patients with known thyroid disease, past use of thyroid hormone therapy, amiodarone and use of any other drug that could affect the thyroid result. The patients were divided into two groups for the comparison as per the thyroid functional status at the end of the 2-year follow-up: Group 1 (normal thyroid function or euthyroidism) and Group 2 (subclinical or OH).

**Study measures**
Clinical data were collected from all the participant records, including demographic details such as family history of thyroid disorder, gestational age at the time of SCH, presence of the goiter, thyroid hormone requirement during pregnancy, and mode of delivery and peripartum complications. The decision to stop levothyroxine after the delivery was taken by the treating physician. We derived the data pertaining to the TSH (at the time of diagnosis, follow-up for the 2 years) and thyroid peroxidase (TPO) antibody status. The Institutional Ethics Committee approved the study protocol for the data analysis. We did not take individual consent from the patients, as the data were derived from the records maintained in the department.

**Definitions**
SCH during pregnancy was defined as having normal free thyroxine (T4) with elevated TSH (more than 2.5 and 3 µIU/ml in first and next trimesters, respectively). SCH after delivery was defined as elevated TSH (>5 µIU/ml) with normal T4. OH was defined as elevated TSH coupled with low T4. Serial thyroid panel was estimated in the patients till the end of the follow-up period. Patients with normal TSH and T4 at the end of the follow-up were defined as euthyroid. A TPO antibody titer of more than 30 IU/L was considered as diagnostic ofAITD.

**Statistical analysis**
Continuous variables data are presented as mean, standard deviation and categorical variables using the frequency and percentages. Unpaired t-test and Chi-square test were used to compare the data between the groups. We did not calculate the power of the study and sample size as our study was purely observational in nature. Univariate logistic regression analysis was done for assessing the risk of permanent hypothyroidism after delivery. A two-tailed \( P < 0.05 \) was considered statistically significant for all the tests. The statistical analysis and graph generation was done using the Graph Pad Prism Software, Version 6 (Graph Pad Software, San Deigo, CA, USA).

**RESULTS**
A total of 559 out of 718 (77.8%) women stopped levothyroxine after delivery. The final follow-up data were available for 467 patients only as shown in Figure 1. At the end of 2 years, 384 (82.2%) remained euthyroid (Group 1) and the remaining 83 (17.8%) developed hypothyroidism (Group 2). SCH and OH were seen in 22 and 61 patients, respectively. Out of the 61 patients who developed OH, 38 developed during the 1st year and the remaining 23 during the 2nd year of follow-up. The clinical and biochemical parameters between both groups are shown in Table 1. Briefly, Group 2 patients had higher mean age, goiter, initial TSH value, and thyroid antibody positivity (\( P < 0.001 \)). The final dose of levothyroxine during the last trimester of pregnancy was significantly higher in hypothyroid women than in euthyroid women. Table 2 shows the findings of the univariate logistic regression analysis for the future risk of hypothyroidism.

**DISCUSSION**
Our study showed that the majority of women with SCH during pregnancy remain euthyroid at the end of 2-year follow-up. The rate of progression to OH depends on the underlying etiology, initial TSH level, TPO antibodies, and goiter. Whickham cohort survey showed that the risk of progression to OH is higher in individuals with high initial TSH-independent of the
Neelaveni, et al.: SCH in pregnancy

The predictive value of TPO antibodies for development of hypothyroidism was evaluated by few authors.\[^{[5,14,19]}\] The natural course of the new onset SCH during pregnancy was evaluated by few authors.\[^{[15-17]}\] Haddow et al. showed that 64% of women developed OH over a decade of follow-up.\[^{[15]}\] The pregnant women in their study had a mean TSH of 13.2 µIU/ml. The reduced progression (18%) observed in our study could be explained by the short duration of follow-up and low value of TSH (7.9 µIU/ml). Our results are similar to that of a recent study with a 5-year follow-up duration that showed the development of OH in 25% of the patients.\[^{[17]}\]

Another important observation from our study is the predictive ability of higher initial TSH during pregnancy (81% of patients with initial TSH >7.5 µIU/ml develop hypothyroidism), for the future risk of hypothyroidism as shown in Table 1. A similar finding was observed in previous studies, where an elevated TSH (>5 µIU/ml) predicted the likelihood of hypothyroidism after delivery.\[^{[16]}\] Future management guidelines should consider the initial TSH value as a marker for recommending continuation of levothyroxine therapy after delivery. AITD was more in patients with hypothyroidism, and higher TPO positivity rates have been observed in Indian pregnant women.\[^{[18]}\] The predictive value of TPO antibodies for progression to OH is shown in several studies.\[^{[5,14,19]}\] Therefore, women with AITD in pregnancy are at a higher risk of future hypothyroidism.

The other finding observed in our study was a higher rate of palpable goiter in hypothyroid group than in euthyroid group. The presence of a goiter in pregnant women could be physiological or pathological with multiple risk factors.\[^{[20]}\] AITD frequently runs in the families and could be responsible for the persistence of a goiter after pregnancy.\[^{[21]}\] The higher levothyroxine requirement during the last trimester in hypothyroid women could be explained by the diminished thyroid reserve and the presence of other risk factors for hypothyroidism. The risk of hypothyroidism could be identified by the goiter, AITD, and higher thyroxine requirement.\[^{[22]}\] The strengths of our study include the seminal nature of the study with a sizeable number of participants. The limitations of our study include retrospective design, diagnosis of thyroid disease based on a single TSH and TPO value and lack of sonological evaluation of the goiter. We did not perform the multivariate analysis, due to the less number of hypothyroidism patients and missing TPO value in a significant proportion of patients. The failure of multivariate analysis and data being derived from a single center are the other limitations of our study.

**Conclusion**

The majority of patients with SCH during pregnancy remain euthyroid after delivery. Advanced age, goiter, positive family history, and thyroid autoimmunity increase the future risk of hypothyroidism in these patients. Large prospective studies with more number of patients are required to study the natural course of SCH detected during pregnancy.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Negro R, Schwartz A, Gisondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab 2010;95:E44-8.

---

**Table 1: Comparison between 2 groups regarding clinical and biochemical parameters**

| Feature                  | Units | Group 1 Euthyroid (n=384) | Group 2 Hypothyroid (n=83) | P  |
|--------------------------|-------|--------------------------|--------------------------|----|
| Age                      | Years | 23.6 (1.9)*              | 25.5 (2.6)               | <0.001 |
| Positive family history  | n (%) | 6 (1.6)                  | 8 (9.6)                  | <0.001 |
| Palpable goiter          | n (%) | 6 (1.6)                  | 42 (50.6)                | <0.001 |
| Initial TSH              | µIU/ml| 5.5 (1.1)                | 7.9 (1.2)                | <0.001 |
| Initial TSH              | <5 µIU/ml | n (%) | 294 (76.6)                  | 6 (7.2)                  | <0.001 |
|                         | Between 5 and 7.5 µIU/ml | n (%) | 56 (14.6)                  | 10 (12)                  | <0.0001 |
|                         | >7.5 µIU/ml | n (%) | 34 (8.9)                  | 67 (80.7)                | <0.001 |
| TPO antibody             |       |                          |                          |                |
| Positive                 | n (%) | 50 (13)                  | 63 (75.9)                | <0.001 |
| Negative                 | n (%) | 221 (57.6)               | 6 (7.2)                  | <0.0001 |
| Not known                | n (%) | 113 (29.4)               | 14 (16.9)                | <0.001 |
| Final LT4 dose           | µg/day| 41.2 (15.2)              | 79.8 (10.5)              | <0.001 |

*Mean (SD). SD: Standard deviation, TSH: Thyroid stimulating hormone, TPO: Thyroid peroxidase

---

**Table 2: Logistic regression model for the risk of development of hypothyroidism**

| Independent variable     | OR    | 95% CI   | P       |
|--------------------------|-------|----------|---------|
| Age                      | 0.66  | 0.59-0.75| <0.0001 |
| Initial TSH              | 0.24  | 0.18-0.32| <0.0001 |
| Positive family history  | 0.15  | 0.05-0.44| <0.0001 |
| Presence of goiter       | 0.02  | 0.01-0.04| <0.0001 |
| Final LT4 dose           | 0.81  | 0.76-0.85| <0.0001 |
| Positive TPO antibody    | 0.02  | 0.01-0.05| <0.0001 |

TSH: Thyroid stimulating hormone, TPO: Thyroid peroxidase, OR: Odds ratio, CI: Confidence interval
2. Benhadi N, Wiersinga WM, Reitsma JB, Vrijkotte TG, Bonsel GJ. Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. Eur J Endocrinol 2009;160:985-91.

3. Karakosta P, Alegakis D, Georgiou V, Roumeliotaki T, Fthenou E, Vassiliki M, et al. Thyroid dysfunction and autoantibodies in early pregnancy are associated with increased risk of gestational diabetes and adverse birth outcomes. J Clin Endocrinol Metab 2012;97:4464-72.

4. Henrichs J, Bongers-Schokking JJ, Schenk JJ, Ghassabian A, Schmidt HG, Visser TJ, et al. Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: The generation R study. J Clin Endocrinol Metab 2010;95:4227-34.

5. Dhanwal DK, Prasad S, Agarwal AK, Dixit V, Banerjee AK. High prevalence of subclinical hypothyroidism during first trimester of pregnancy in North India. Indian J Endocrinol Metab 2013;17:281-4.

6. Rajput R, Goel V, Nanda S, Rajput M, Seth S. Prevalence of thyroid dysfunction among women during the first trimester of pregnancy at a tertiary care hospital in Haryana. Indian J Endocrinol Metab 2015;19:416-9.

7. Gayathri R, Lavanya S, Raghavan K. Subclinical hypothyroidism and autoimmune thyroiditis in pregnancy: A study in South Indian subjects. JAPI 2009;57:691-3.

8. Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. 2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. J Clin Endocrinol Metab 2014;103:76-94.

9. De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, et al. Management of thyroid dysfunction during pregnancy and postpartum: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2543-65.

10. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011;21:1081-25.

11. Diez JJ, Iglesias P. Spontaneous subclinical hypothyroidism in patients older than 55 years: An analysis of natural course and risk factors for development of overt thyroid failure. J Clin Endocrinol Metab 2004;89:4890-7.

12. Paney A, Das V, Agarwal A, Agrawal S, Misra D, Jaiswal N. Evaluation of obstetric near miss and maternal deaths in a tertiary care hospital in North India: Shifting focus from mortality to morbidity. J Obstet Gynaecol India 2014;64:394-9.

13. Huber G, Staub JJ, Meier C, Mitra C, Guglielmetti M, Huber P, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: Prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002;87:3221-6.

14. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995;43:55-68.

15. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999;341:549-55.

16. Strieder TG, Tijssen JG, Wenzel BE, Endert E, Wiersinga WM. Prediction of progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score. Arch Intern Med 2008;168:1657-63.

17. Shields BM, Knight BA, Hill AV, Hattersley AT, Vaidya B. Five-year follow-up for women with subclinical hypothyroidism in pregnancy. J Clin Endocrinol Metab 2013;98:E1941-5.

18. Jayaraman M, Verma A, Harikumar KV, Ugale M, Modi K. Pregnancy outcomes with thyroxine replacement for subclinical hypothyroidism: Role of thyroid autoimmunity. Indian J Endocrinol Metab 2013;17:294-7.

19. van den Boogaard E, Vissenberg R, Land JA, van Wely M, Ven der Post JA, Goddijn M, et al. Significance of (sub) clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: A systematic review. Hum Reprod Update 2016;22:532-3.

20. Glinnöer D, Lemone M. Goiter and pregnancy: A new insight into an old problem. Thyroid 1992;2:65-70.

21. Galofre JC, Davies TF. Autoimmune thyroid disease in pregnancy: A review. J Womens Health (Larchmt) 2009;18:1847-56.

22. Krassas GE, Poppe K, Glinnöer D. Thyroid function and human reproductive health. Endocr Rev 2010;31:702-55.